Reportable Cancer List DX 10/2022 or later

REPORTABLE CASES – MISSISSIPPI

For cases diagnosed 10/1/2022 and after

The following lists are intended to assist you, as the reporter, in identifying the reportable neoplasms for your facility. Any reportable neoplasms diagnosed on or after January 1, 1996 should be reported to the Mississippi Cancer Registry.

• Malignant neoplasms (Behavior 2 and 3) (exclusions noted below)
• Benign and borderline neoplasms of the central nervous system (Cases diagnosed on or after January 1, 2004)

• Squamous intraepithelial neoplasia grade III of vulva [VIN], vagina [VAIN], and anus [AIN] beginning with 2001 cases.
• Carcinoid, NOS of the appendix is reportable and should be coded with a behavior of 3 (Cases diagnosed on or after January 1, 2015)
• Lobular neoplasia grade III (LN III)/lobular intraepithelial neoplasia grade III (LIN III) breast C500-C509 (January 1, 2016 and forward)
• Pancreatic intraepithelial neoplasia (PanIN III) (January 1, 2016 and forward)
• Penile intraepithelial neoplasia III (PeIN III) (January 1, 2016 and forward)
• GIST tumors, all histologies changed to behavior 3 in ICD-O-3.2 (Cases diagnosed January 1, 2021 and later).

• Thymoma, most behaviors changed to 3 in ICD-O-3.2 (January 1, 2021 and later).

• GIST, NOS with multiple tumor foci and/or metastatic to lymph nodes or distant sites (Prior to January 1, 2021)
• Early or evolving melanoma in situ, or any other early or evolving melanoma beginning January 1, 2021 and forward.
• Low-grade appendiceal mucinous neoplasm (LAMN) behavior changed to 2 effective January 1, 2022.
• High-grade appendiceal mucinous neoplasm (HAMN) behavior changed to 2 effective January 1, 2022.

These are just some highlighted reportable conditions. For all reportable histologies, refer to https://www.naaccr.org/icdo3/ for the lists of reportable conditions reportable as of January 1, 2023.

• Skin cancers (C44._) with histologies 8000-8005, 8010-8046, 8050-8084, 8090-8110
• CIS of the cervix and CIN III and SIN III
• PIN III (January 1, 2001 and later)
• Borderline cystadenomas (ICD-O-3 Histologies 8442, 8451, 8462, 8472, 8473), of the ovaries with behavior code “1” are not collected as of January 1, 2001
• Cyst, brain or CNS tumor that does not have an ICD-O-3 code as of January 1, 2004
• Colorectal tumors with the following morphologic description:
  • Serrated dysplasia, high grade
  • Adenomatous polyp, high grade dysplasia
  • Tubular adenoma, high grade
  • Villous adenoma, high grade
  • Tubulovillous adenoma, high grade
• Microscopic thymoma or thymoma benign (8580/0), micronodular thymoma with lymphoid stroma (8580/1), and ectopic hamartomatous thymoma (8587/0)

These are just some highlighted non-reportable conditions. For all reportable/non-reportable histologies, refer to https://www.naaccr.org/icdo3/ for the lists of reportable/non-reportable conditions as of January 1, 2023.

All diagnostic reports should be reviewed for reportability. If the terminology is ambiguous, use the following list to determine if the case should be reported.

** Do not substitute synonyms such as "supposed" for "presumed" or "equal" for "comparable." Do not substitute "likely" for "most likely." Use on the exact words on the list.

Exceptions:

• If a cytology is reported using any ambiguous term, do not interpret it as a diagnosis of cancer. Abstract the case only if a positive biopsy or a physician’s clinical impression of cancer supports the cytology findings.
• Genetic findings in the absence of pathologic or clinical evidence of reportable disease are indicative of risk only and do not constitute a diagnosis.

COMPREHENSIVE ICD-10-CM CASEFINDING CODE LIST FOR REPORTABLE TUMORS

¹ Note: Beginning with cases diagnosed 1/1/2023, pilocytic astrocytoma are coded 9421/1. Cases diagnosed prior to 1/1/2023 are coded 9421/3.

SUPPLEMENTAL CASEFINDING LIST TO BE SCREENED FOR REPORTABLE CONDITIONS

Cases with the following codes should be screened as time allows. Experience has shown that use of this supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms and other reportable diseases and treatment related information.